Celgene Corporation (CELG) Shares are Up 2.98%

Celgene Corporation (CELG) : Traders are bullish on Celgene Corporation (CELG) as it has outperformed the S&P 500 by a wide margin of 7.33% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.54%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.98% in the last 1 week, and is up 10% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Celgene Corporation (NASDAQ:CELG): The stock opened at $116.77 on Friday but the bulls could not build on the opening and the stock topped out at $117.90 for the day. The stock traded down to $115.36 during the day, due to lack of any buying support eventually closed down at $115.53 with a loss of -0.64% for the day. The stock had closed at $116.27 on the previous day. The total traded volume was 4,972,905 shares.

The stock has recorded a 20-day Moving Average of 7.5% and the 50-Day Moving Average is 10.69%. Celgene Corporation is up 15.24% in the last 3-month period. Year-to-Date the stock performance stands at -3.53%.

Celgene Corporation (CELG) : The consensus price target for Celgene Corporation (CELG) is $142.47 for the short term with a standard deviation of $12.1. The most optimist securities analyst among the 15 who monitor the stock believes that the stock can reach $162, however, the pessimist price target for the company is $120.


Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.